Pruritus
Drug research and approvals for pruritus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 59 studies of pruritus are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 7 approved and 2 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 59
- Trials authorized in Canada: 2
- FDA orphan approvals: 7
- EU medicines: 4
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 · Phase 3 · Arcutis Biotherapeutics, Inc. · starts Oct 30, 2026
- Observational Analytical Validation Study of the Replior ScratchSenseNCT07909967 · Not reported · Replior AB · starts Oct 12, 2026
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates…NCT07898475 · Not reported · Dr. Amara Safdar · starts Oct 2, 2026
- Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque PsoriasisNCT07844772 · Not reported · Istanbul Training and Research Hospital · starts Jun 11, 2026
- A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic…NCT07811869 · Phase 3 · Novartis Pharmaceuticals · starts Oct 7, 2026
- A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic…NCT07700056 · Phase 3 · Novartis Pharmaceuticals · starts Aug 24, 2026
- A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by DermatophytesNCT07668999 · Phase 1 · Sinomune Pharmaceutical Co., Ltd · starts Mar 31, 2027
- tDCS for Reducing the Incidence of OEI After Cesarean SectionNCT07569783 · Not applicable · Affiliated Hospital of Nantong University · starts May 10, 2026
- Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis…NCT07560618 · Phase 4 · Integrative Skin Science and Research · starts Jul 21, 2026
Approved 24 of 38
- DifelikefalinKappa opioid receptor agonist
- LidocaineSodium channel alpha subunit blocker
- CetirizineHistamine H1 receptor antagonist
- LoratadineHistamine H1 receptor antagonist
- BepotastineHistamine H1 receptor antagonist
- DoxepinNorepinephrine transporter inhibitor
- PromethazineHistamine H1 receptor antagonist
- ThenalidineHistamine H1 receptor antagonist
- Phenol
- Zinc oxideSunscreen/skin protectant
- PyrilamineHistamine H1 receptor antagonist
- OlopatadineHistamine H1 receptor antagonist
- ClemastineHistamine H1 receptor antagonist
- TripelennamineHistamine H1 receptor antagonist
- HydroxyzineHistamine H1 receptor antagonist
- DiphenhydramineHistamine H1 receptor antagonist
- PheniramineHistamine H1 receptor antagonist
- DibucaineSodium channel protein type V alpha subunit blocker
- Hydrocortisone acetateGlucocorticoid receptor agonist
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- PhenylephrineAdrenergic receptor alpha-1 agonist
- ClotrimazoleCytochrome P450 51 inhibitor
- MiconazoleCytochrome P450 51 inhibitor
- BenoxinateSodium channel alpha subunit blocker
Phase 3 12
- LinerixibatIleal bile acid transporter inhibitor
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- MorphineMu opioid receptor agonist
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- GabapentinVoltage-gated calcium channel modulator
- Fospropofol
- NalbuphineOpioid receptors; mu/kappa/delta agonist
- OxycodoneMu opioid receptor agonist
- FexofenadineHistamine H1 receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- Cannabinol
- Syrup
Phase 2 12 of 19
- SertralineSerotonin transporter inhibitor
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- PAC-14028Vanilloid receptor antagonist
- SerlopitantNeurokinin 1 receptor antagonist
- AmitriptylineSerotonin transporter inhibitor
- GranisetronSerotonin 3a (5-HT3a) receptor antagonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- AprepitantNeurokinin 1 receptor antagonist
- MebendazoleTubulin inhibitor
- PregabalinVoltage-gated calcium channel modulator
- ItacitinibTyrosine-protein kinase JAK1 inhibitor
- Stapokibart
Phase 1 or earlier 10
- AcetaminophenCyclooxygenase inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Obeticholic acidBile acid receptor FXR agonist
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
- CapsaicinVanilloid receptor opener
- TradipitantNeurokinin 1 receptor antagonist
- Carbomer 910
- VixarelimabOncostatin-M-specific receptor subunit beta inhibitor
- CamlipixantP2X purinoceptor 3 antagonist
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
How its trials ended
304 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 68 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.
- Completed, result not reported16053%
- Ongoing4414%
- Met its primary endpoint3311%
- Status unknown3211%
- Stopped: other or unclear176%
- Missed its primary endpoint52%
- Stopped: enrollment or feasibility52%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Jun 5, 2025 | Randomized double-blind placebo-controlled phase 3 study to evaluate the efficacy and safety of maralixibat in the treatment of participants with cholestatic…Maralixibat | Mirum Pharmaceuticals | Ongoing |
| Aug 3, 2022 | Randomized, double-blind, placebo-controlled study to evaluate the effects of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis or…EP547 | Escient Pharmceuticals Inc | Closed |
| Mar 17, 2026 | LynavoyTreatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients | Intercept Pharmaceuticals, Inc. (A wholly owned subsidiary of Alfasigma S.p.A.) | Approved |
| Jul 24, 2024 | LivmarliTreatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Approved |
| Mar 13, 2024 | LivmarliTreatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC) | Mirum Pharmaceuticals, Inc. | Approved |
| Jun 13, 2023 | BylvayTreatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS) | Ipsen Biopharmaceuticals, Inc. | Approved |
| Mar 13, 2023 | LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older | Mirum Pharmaceuticals, Inc. | Approved |
| Sep 29, 2021 | LivmarliTreatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older | Mirum Pharmaceuticals, Inc. | Approved |
| Jul 20, 2021 | BylvayTreatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use:… | Ipsen Biopharmaceuticals, Inc. | Approved |
| Nov 23, 2010 | NaloxoneTopical treatment of pruritus associated with mycosis fungoides | Elorac, Inc. | Designated |
| Sep 3, 2004 | Buffered Ursodeoxycholic AcidTreatment of pruritus in patients with Alagille Syndrome | Digestive Care, Inc. | Designated |
| Oct 22, 2026 | LynavoyLinerixibat · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Sep 19, 2024 | KayfandaOdevixibat | Ipsen Pharma | EMA ↗ |
| Dec 9, 2022 | LivmarliMaralixibat chloride · orphan | Mirum Pharmaceuticals International B.V. | EMA ↗ |
| Apr 25, 2022 | KapruviaDifelikefalin | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA